Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Ana Drozdowskyj, Cinta Pallarés et al.|The Lancet Oncology|2012Cited by 5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung CancerRafael Rosell, Miquel Tarón, Teresa Morán et al.|New England Journal of Medicine|2009Cited by 2.4k
Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung CancerEnriqueta Felip, Bartomeu Massutí|Journal of Clinical Oncology|2010Cited by 426
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.Rámón Colomer, Belén Lloveras, Sagrario Montero et al.|PubMed|2000Cited by 172